CDKN2A and central nervous system cancer: A previous report indicated that five of seven pediatric grade II–IV astrocytomas with BRAFV600E had concomitant CDKN2A HD [59] and CDKN2A deletions combined with BRAFV600E alterations, constituting a subgroup of secondary high-grade gliomas [60].